Weinberg Describes the Available Options for Patients With GIST
Benjamin Weinberg, MD, assistant professor of medicine, and attending physician, Georgetown University Hospital, Medstar Health, discusses the overall prognosis of patients with gastrointestinal stromal tumors.
Benjamin Weinberg, MD, assistant professor of medicine, and attending physician, Georgetown University Hospital, Medstar Health, discusses the overall prognosis of patients with gastrointestinal stromal tumors (GIST).
GIST has an interesting growth pattern, says Weinberg. It develops from the stromal tissue, which allows GIST to present anywhere along the gastrointestinal tract. In most cases, if the tumor is surgically removed, outcomes are good. Then, oncologists have to decide if it is necessary to administer therapy after surgery and which form of therapy is optimal. Weinberg notes that the typical drug used for the treatment of a patient after surgical resection is imatinib (Gleevac), which is given for 1 to 3 years and followed by a curative surgical resection if the patient is high-risk.
In patients with metastatic GIST, physicians also use imatinib, but they profile patients beforehand to ensure that the patient can respond to the drug. There are other drugs, which are similar to imatinib, and can target other poly kinases in patients who are refractory to imatinib.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
